The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

By Beaver Julia A   Park Ben H  

Future Oncology, Vol. 8, Iss. 6, 2012-06 ,pp. : 651-657

Future Medicine

Access to resources Recommend Favorite

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment

By Kvinnsland S.   Anker G.   Dirix L.-Y.   Bonneterre J.   Prove A.-M.   Wilking N.   Lobelle J.-P.   Mariani O.   di Salle E.   Polli A.   Massimini G.  

European Journal of Cancer, Vol. 36, Iss. 8, 2000-05 ,pp. : 976-982

Elsevier

Access to resources Recommend Favorite

Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors

By  

Current Cancer Therapy Reviews, Vol. 6, Iss. 1, 2010-02 ,pp. : 51-61

Bentham Science Publishers

Access to resources Recommend Favorite

Examination of the use of Exemestane in patients with metastatic breast cancer

By Takashima Seiki  

Breast Cancer, Vol. 18, Iss. 3, 2011-07 ,pp. : 189-194

Springer Publishing Company

Access to resources Recommend Favorite

Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Aminoglutethimide: a Phase II Multicentre Multinational Study

By Exemestane Study Group   Thurlimann B.   Paridaens R.   Serin D.   Bonneterre J.   Roche H.   Murray R.   di Salle E.   Lanzalone S.   Zurlo M.G.   Piscitelli G.  

European Journal of Cancer, Vol. 33, Iss. 11, 1997-10 ,pp. : 1767-1773

Elsevier

Access to resources Recommend Favorite